Susan M. Ludeman
- Molecular Biology
- Oncology top 10%
- Cancer Research top 10%
- Pathology and Forensic Medicine top 5%
- Public Health, Environmental and Occupational Health top 10%
- Co-authors
- O. Michael ColvinJames B. SpringerClayton A. SmithRobert W. StormsLisa ShahGerald ZonWilliam EganM. Eileen Dolan
- Topics
- Chemotherapy-induced organ toxicity mitigation (19 papers)Organophosphorus compounds synthesis (11 papers)Chemical Reactions and Isotopes (11 papers)
- Cited by
- Cancer ResearchHematologyOncology
- Journals
- Proceedings of the National Academy of SciencesJournal of the American Chemical SocietyCancer Research
- Partner nations
- United StatesSouth KoreaCanada
In The Last Decade
Susan M. Ludeman
51 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 106
- Molecular Biology 593
- Oncology 387
- Cancer Research 264
- Pathology and Forensic Medicine 226
- Public Health, Environmental and Occupational Health 215
Countries citing papers authored by Susan M. Ludeman
This map shows the geographic impact of Susan M. Ludeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan M. Ludeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan M. Ludeman more than expected).
Fields of papers citing papers by Susan M. Ludeman
This network shows the impact of papers produced by Susan M. Ludeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan M. Ludeman. The network helps show where Susan M. Ludeman may publish in the future.
Co-authorship network of co-authors of Susan M. Ludeman
This figure shows the co-authorship network connecting the top 25 collaborators of Susan M. Ludeman. A scholar is included among the top collaborators of Susan M. Ludeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan M. Ludeman. Susan M. Ludeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 71 | |
| 2 | 17 | |
| 3 | 3 | |
| 4 | 18 | |
| 5 | Cyclophosphamide, but not melphalan or carboplatin, synergistically enhanced topotecan activity against Ewing’s family tumor cell lines in hypoxia | 1 |
| 6 | 5 | |
| 7 | 8 | |
| 8 | 6 | |
| 9 | 35 | |
| 10 | 131 | |
| 11 | 17 | |
| 12 | 4 | |
| 13 | 16 | |
| 14 | 20 | |
| 15 | 11 | |
| 16 | 6 | |
| 17 | 26 | |
| 18 | 2 | |
| 19 | 4 | |
| 20 | 27 |
About Susan M. Ludeman
Susan M. Ludeman is a scholar working on Pharmaceutical Science, Pathology and Forensic Medicine and Cancer Research, having authored 51 papers that have together received 1.4k indexed citations. Recurring topics across this work include Chemotherapy-induced organ toxicity mitigation (19 papers), Organophosphorus compounds synthesis (11 papers) and Chemical Reactions and Isotopes (11 papers). The work is most often cited by research in Cancer Research (264 citations), Hematology (162 citations) and Oncology (387 citations). Susan M. Ludeman has collaborated with scholars based in United States, South Korea and Canada. Frequent co-authors include O. Michael Colvin, James B. Springer, Clayton A. Smith, Robert W. Storms, Lisa Shah, Gerald Zon, William Egan, M. Eileen Dolan, Victoria L. Boyd and Michael P. Gamcsik. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.